ABL1 Kinase Domain Mutation Analysis
Sequencing
Indication
- .To evaluate the basis for resistance (primary or acquired) to tyrosine kinase inhibitors (TKIs) in patients with Philadelphia-chromosome positive leukemias such as CML and B-ALL
- Progression to accelerated phase or blast phase in CML patients.
Methodology
The presence of point mutations in the ABL1 kinase domain of the BCR-ABL1 fusion gene (codons 221-500) is assessed by direct Sanger sequencing of the BCR-ABL1 fusion transcripts following nested PCR.
Test Parameters
The result will include the codon number, amino acid changes and relative abundance of the mutation(s) found. This test will detect mutated transcript that comprise at least 10% of total BCR-ABL1 fusion transcripts in sample.
Turnaround Time
10 days
Sample Requirements
- 10 mls peripheral blood (PB) in purple top tube (EDTA Vacutainer), sent on wet ice
or
- 2-5 ml of bone marrow aspirate (BM), sent on wet ice
or
- 20 µg of purified RNA, sent on dry ice
or
- 10 µg of cDNA, sent on dry ice
CPT Codes
81403
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.